D. Hanahan and L. M. Coussens, Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, vol.21, pp.309-331, 2012.

R. Boissier, J. Campagna, N. Branger, G. Karsenty, and E. Lechevallier, The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review, Urol Oncol, vol.35, pp.135-176, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01792761

F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, vol.30, pp.1073-81, 2009.

J. Vandercappellen, J. Van-damme, and S. Struyf, The role of CXC chemokines and their receptors in cancer, Cancer Lett, vol.267, pp.226-270, 2008.

A. Sparmann and D. Bar-sagi, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, Cancer Cell, vol.6, pp.447-58, 2004.

C. Alfaro, M. F. Sanmamed, M. E. Rodriguez-ruiz, A. Teijeira, C. Onate et al., Interleukin-8 in cancer pathogenesis, treatment and follow-up, Cancer Treat Rev, vol.60, pp.24-31, 2017.

K. Echizen, O. Hirose, Y. Maeda, and M. Oshima, Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways, Cancer Sci, vol.107, pp.391-398, 2016.

H. Verbeke, K. Geboes, J. Van-damme, and S. Struyf, The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer, Biochim Biophys Acta, vol.1825, pp.117-146, 2012.

H. Verbeke, S. Struyf, G. Laureys, and J. Van-damme, The expression and role of CXC chemokines in colorectal cancer, Cytokine Growth Factor Rev, vol.22, pp.345-58, 2011.

A. S. Payne and L. A. Cornelius, The role of chemokines in melanoma tumor growth and metastasis, J Invest Dermatol, vol.118, pp.915-937, 2002.

M. Dufies, S. Giuliano, J. Viotti, D. Borchiellini, L. S. Cooley et al., CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas, Br J Cancer, vol.117, pp.947-53, 2017.

R. Grepin, M. Guyot, S. Giuliano, M. Boncompagni, D. Ambrosetti et al., The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma, Cancer Res, vol.74, pp.873-83, 2014.

L. P. Chan, L. F. Wang, F. Y. Chiang, K. W. Lee, P. L. Kuo et al., IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway, Oncotarget, vol.7, pp.61820-61851, 2016.

H. Miyazaki, V. Patel, H. Wang, R. K. Edmunds, J. S. Gutkind et al., Down-regulation of CXCL5 inhibits squamous carcinogenesis, Cancer Res, vol.66, pp.4279-84, 2006.

G. Zhu, Y. Tang, N. Geng, M. Zheng, J. Jiang et al., HIF-alpha/MIF and NF-kappaB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC, Neoplasia, vol.16, pp.168-79, 2014.

H. An, L. Xu, Y. Chang, Y. Zhu, Y. Yang et al., CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma, Eur J Cancer, vol.51, pp.1953-61, 2015.

H. Ha, B. Debnath, and N. Neamati, Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases, Theranostics, vol.7, pp.1543-88, 2017.

H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat et al., The Protein Data Bank, Nucleic Acids Res, vol.28, pp.235-277, 2000.

G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew et al., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J Comput Chem, vol.30, pp.2785-91, 2009.

G. Wolber and T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J Chem Inf Model, vol.45, pp.160-169, 2005.

O. Trott and A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, vol.31, pp.455-61, 2010.

J. Gioanni, J. L. Fischel, J. C. Lambert, F. Demard, C. Mazeau et al., Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment, Eur J Cancer Clin Oncol, vol.24, pp.1445-55, 1988.

R. Grepin, D. Ambrosetti, A. Marsaud, L. Gastaud, J. Amiel et al., The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma, PLoS ONE, vol.9, p.89449, 2014.

M. Dufies, A. Jacquel, N. Belhacene, G. Robert, T. Cluzeau et al., Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells, Oncotarget, vol.2, pp.874-85, 2011.

R. B. Badisa, S. F. Darling-reed, P. Joseph, J. S. Cooperwood, L. M. Latinwo et al., Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells, Anticancer Res, vol.29, pp.2993-2999, 2009.

J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, vol.6, p.1, 2013.

E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-405, 2012.

S. R. Leong, R. C. Kabakoff, and C. A. Hebert, Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction, J Biol Chem, vol.269, pp.19343-19351, 1994.

D. Calebiro and A. Godbole, Internalization of G-protein-coupled receptors: Implication in receptor function, physiology and diseases, Best Pract Res Clin Endocrinol Metab, vol.32, pp.83-91, 2018.

J. Busch-petersen, D. C. Carpenter, M. Burman, J. Foley, G. E. Hunsberger et al., Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2, J Pharmacol Exp Ther, vol.362, pp.338-384, 2017.

R. Grepin, M. Guyot, M. Jacquin, J. Durivault, E. Chamorey et al., Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines, Oncogene, vol.31, pp.1683-94, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00824206

S. Giuliano, Y. Cormerais, M. Dufies, R. Grepin, P. Colosetti et al., Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux, Autophagy, vol.11, pp.1891-904, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02108861

M. Lupu-plesu, A. Claren, S. Martial, N. 'diaye, P. D. Lebrigand et al., Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma, Oncogenesis, vol.6, p.354, 2017.

M. Dufies, S. Giuliano, D. Ambrosetti, A. Claren, P. D. Ndiaye et al., Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas, Cancer Res, vol.77, pp.1212-1238, 2017.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, A. Frontera, O. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.378, pp.1277-90, 2018.

M. B. Atkins and N. M. Tannir, Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma, Cancer Treat Rev, vol.70, pp.127-164, 2018.

T. Y. Seiwert, J. K. Salama, and E. E. Vokes, The chemoradiation paradigm in head and neck cancer, Nat Clin Pract Oncol, vol.4, pp.156-71, 2007.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, vol.68, pp.394-424, 2018.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-74, 2011.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

J. Moskovitz, J. Moy, and R. L. Ferris, Immunotherapy for Head and Neck Squamous Cell Carcinoma, Curr Oncol Rep, vol.20, p.22, 2018.

E. Saada-bouzid, C. Defaucheux, A. Karabajakian, V. P. Coloma, V. Servois et al., Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.28, pp.1605-1616, 2017.

Y. G. Najjar, P. Rayman, X. Jia, P. G. Pavicic, J. Rini et al., Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1beta, IL8, CXCL5, and Mip-1alpha, Clin Cancer Res, vol.23, pp.2346-55, 2017.